Stock XVIVO XVIVO PERFUSION AB
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:46 17/05/2024 BST 		5-day change 1st Jan Change
392 SEK -1.01% Intraday chart for Xvivo Perfusion AB +2.62% +18.97%
04-24 Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest DJ
04-24 Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest
DJ
Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague
CI
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published
CI
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial
CI
US Food & Drug Administration Grants Xvivo Perfusion AB Approval to Include DCD Heartarts in IDE Clinical Trial
CI
Xvivo Perfusion AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Xvivo Perfusion AB Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated
CI
XVIVO Perfusion AB Enters into A Strategic Collaboration with MTJ Aviation to Strengthen Organ Procurement Services in the US
CI
Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology
CI
Patient Inclusion Completed in European Clinical Trial with XVIVO's Heart Preservation Technology
CI
Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
XVIVO Perfusion Purchases Machine and Perfusion Unit from Avionord in Carve-Out
MT
Xvivo Perfusion AB (OM:XVIVO) completed the acquisition of Machine and perfusion business of Avionord Srl from Avionord S.r.l. for Ç12 million.
CI
Xvivo Perfusion AB Presents Positive Results from the Australian & New Zealand Heart Preservation Study
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XVIVO Stock
  4. News Xvivo Perfusion AB
  5. Highlights